發(fā)布時(shí)間：2018-06-19 23:32

  本文選題：前列腺癌 + 雄激素受體剪切變異體　； 參考：《南昌大學(xué)》2017年碩士論文

【摘要】：目的:前列腺癌去勢(shì)抵抗和遠(yuǎn)處轉(zhuǎn)移是治療的難點(diǎn),其發(fā)生的確切機(jī)制目前尚不明確。大量研究表明雄激素受體剪切變異體與前列腺癌的進(jìn)展和轉(zhuǎn)移有密切關(guān)系。本研究擬探索AR-V7表達(dá)在前列腺癌進(jìn)展及其骨轉(zhuǎn)移過程中的臨床意義。方法:篩選2015年1月-2017年4月在南昌大學(xué)第一附屬醫(yī)院泌尿外科就診且相關(guān)檢查資料完整的51例患者作為研究對(duì)象。51例患者中前列腺增生患者20例,年齡58-77(平均65.8)歲;局限性前列腺癌患者20例,年齡59-76(平均67.5)歲;前列腺癌伴骨轉(zhuǎn)移患者11例,年齡52-81(平均66)歲。三組患者的年齡差異無統(tǒng)計(jì)學(xué)意義。所有患者均經(jīng)過手術(shù)后的病理檢查確診,收集患者手術(shù)后的前列腺病理組織標(biāo)本。采用免疫組化染色法和qRT-PCR分別檢測(cè)AR-V7蛋白和AR-V7m RNA在前列腺增生組織、局限性前列腺癌組織、伴骨轉(zhuǎn)移的前列腺癌組織中表達(dá)情況。利用SPSS20.0統(tǒng)計(jì)軟件分析三組標(biāo)本中AR-V7的表達(dá)量差異。結(jié)果:1、AR-V7蛋白的表達(dá)以細(xì)胞核中出現(xiàn)棕黃色顆粒為陽性表達(dá)。免疫組化顯示AR-V7在三組不同前列腺標(biāo)本中的陽性表達(dá)量分別為:前列腺增生標(biāo)本組中無陽性表達(dá);局限性前列腺癌標(biāo)本組有3例陽性表達(dá),該組陽性表達(dá)率15%;前列腺癌伴骨轉(zhuǎn)移標(biāo)本組AR-V7有6例陽性表達(dá),該組陽性表達(dá)率54.5%,差異有統(tǒng)計(jì)學(xué)意義(P0.005)。2、qRT-PCR檢測(cè)組織標(biāo)本結(jié)果顯示:前列腺病理標(biāo)本中AR-V7 m RNA表達(dá)量在前列腺增生組、局限性前列腺癌組、前列腺癌伴骨轉(zhuǎn)移組依次顯著上調(diào),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:AR-V7的表達(dá)量在前列腺增生、局限性前列腺癌、伴骨轉(zhuǎn)移的前列腺癌病理組織中依次增高。AR-V7可能與前列腺癌進(jìn)展和骨轉(zhuǎn)移的發(fā)生密切相關(guān)。
[Abstract]:Objective: castration resistance and distant metastasis of prostate cancer are difficult to be treated. A large number of studies have shown that androgen receptor splicing variants are closely related to the progression and metastasis of prostate cancer. This study was to explore the clinical significance of AR-V 7 expression in the progression and bone metastasis of prostate cancer. Methods: from January 2015 to April 2017, 51 patients with benign prostatic hyperplasia (BPH), aged 58-77 (mean 65.8 years), were selected from urology department of the first affiliated Hospital of Nanchang University. There were 20 patients with localized prostate cancer (mean 67.5 years old) and 11 patients with prostate cancer with bone metastasis (mean 66 years old). There was no significant difference in age among the three groups. All the patients were confirmed by pathological examination after operation, and the pathological specimens of prostate were collected. Immunohistochemical staining and qRT-PCR were used to detect the expression of AR-V7 protein and AR-V7 mRNA in prostatic hyperplasia tissues, localized prostate cancer tissues and prostate cancer tissues with bone metastasis, respectively. The expression of AR-V7 in the three groups was analyzed by SPSS 20.0 software. Results the positive expression of AR-V 7 protein in the nucleus was found in brown granules. Immunohistochemical staining showed that there was no positive expression of AR-V7 in three groups of prostate specimens: no positive expression of AR-V7 was found in benign prostatic hyperplasia group and 3 cases in localized prostate cancer group. There were 6 cases of AR-V7 positive expression in prostate cancer with bone metastasis. The positive expression rate of AR-V7 mRNA was significantly higher in prostate hyperplasia group, localized prostate cancer group and prostate cancer with bone metastasis group. The difference was statistically significant (P 0.05). Conclusion the increased expression of V7 in prostate cancer tissues with benign prostatic hyperplasia, localized prostate cancer and bone metastasis may be closely related to the progression of prostate cancer and the occurrence of bone metastasis.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 饒?zhí)?陳捷;孫庭;王共先;;雄激素受體剪接變異體在前列腺癌去勢(shì)抵抗轉(zhuǎn)化中的研究進(jìn)展[J];中華實(shí)驗(yàn)外科雜志;2016年12期

2 劉攀;姜睿;;前列腺癌骨病診斷和治療的進(jìn)展[J];臨床泌尿外科雜志;2016年08期

3 周利群;;中國前列腺癌藥物去勢(shì)治療專家共識(shí)[J];中華泌尿外科雜志;2016年07期

4 劉繼紅;諶科;王濤;;前列腺癌的基礎(chǔ)研究進(jìn)展[J];中華實(shí)驗(yàn)外科雜志;2015年12期

5 瞿元元;葉定偉;戴波;孔蘊(yùn)毅;蔡旭;常坤;孫自捷;張海梁;朱耀;施國海;;前列腺癌組織中雄激素受體剪接變異體7表達(dá)對(duì)轉(zhuǎn)移性前列腺癌患者激素敏感時(shí)間的預(yù)測(cè)作用[J];中華泌尿外科雜志;2014年08期

6 吳開杰;寧忠運(yùn);賀大林;;去勢(shì)抵抗性前列腺癌中雄激素受體信號(hào)通路再激活的研究進(jìn)展[J];中華泌尿外科雜志;2014年03期

7 韓蘇軍;張思維;陳萬青;李長(zhǎng)嶺;;中國前列腺癌發(fā)病現(xiàn)狀和流行趨勢(shì)分析[J];臨床腫瘤學(xué)雜志;2013年04期

，

本文編號(hào)：2041829